Loading the session
Loading the session
Loading instrument
$8.89
−0.34%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:39 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +15.1% (SPY −1.6%, XLV +13.5%). 3 months: +127.0% (SPY −0.4%, XLV +15.5%). 1 year: +47.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CAPR, SPY and XLV · as of 4 Nov 2026
19.9M shares were sold short at the 15 Oct 2026 settlement, 34.2% of the 58.1M shares outstanding; covering them would take 6.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $8.92 was 9.9% above its 50-day average ($8.12) and 56.5% below its 200-day average ($20.52). It has closed below the 200-day for 85 sessions, since 7 Jul 2026. The 50-day average crossed below the 200-day on 3 Aug 2026, 66 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $8.92 on 4 Nov 2026: 77.9% below the 52-week high of $40.37 (3 Dec 2025) and 201.4% above the low of $2.96 (30 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
4 Nov 2026 volume of 6.4M shares was 1.9× the average of the 30 sessions before it (3.5M), as the price rose 8.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
August 14, 2026
+57.96%July 27, 2026
−64.49%December 3, 2025
+371.07%